Clean Science Q1 FY27: Record Sales, HALS Scale-Up

Key takeaway from the earnings call

Clean Science and Technology Ltd reported its highest-ever consolidated quarterly sales in Q1 FY27, even as management flagged a challenging operating backdrop. In the earnings call held on August 1, 2026, the company pointed to geopolitical headwinds affecting raw material supply chains and costs. It also cited non-availability of shipping vessels that disrupted timely exports and created supply-side constraints. A temporary shutdown at a key Indian propylene supplier further affected production for about two weeks, based on management commentary referenced in the call notes. Despite these constraints, the company said it maintained operational stability and continued to execute on value-creation initiatives.

Consolidated performance: record sales and steady profitability

Management indicated consolidated sales of approximately INR 264 crore for Q1 FY27, described as the highest in the company’s history. The same set of published numbers in the provided material also lists consolidated revenue from operations at ₹2,684.32 million, which equals INR 268.432 crore, and was up year-on-year from ₹2,428.69 million (INR 242.869 crore). On a sequential basis, consolidated revenue growth was described as 7% to about INR 264 crore.

On profitability, the company reported consolidated EBITDA of INR 96 crore with an EBITDA margin of 37%. Consolidated profit after tax (PAT) stood at INR 73 crore with a PAT margin of 28%. The management narrative attributed the year-on-year revenue increase primarily to the scale-up of the HALS business.

Standalone numbers: realisation-led revenue improvement

On a standalone basis, Q1 FY27 revenue was reported at INR 203 crore on a sequential basis, up 5% quarter-on-quarter, largely due to improved realisations across products. A separate financial-results line item in the material also lists standalone revenue for Q1 FY27 at ₹2,071.04 million, which equals INR 207.104 crore, up from ₹1,971.30 million (INR 197.130 crore) a year earlier.

Standalone EBITDA margin was stated at 43%, translating into EBITDA of INR 87 crore. Standalone PAT margin was stated at 36%, translating into PAT of INR 73 crore. Management also indicated that Q4 FY26 EBITDA and PAT, after excluding a one-off operating expense, were roughly INR 83 crore and INR 53 crore respectively, and used that to contextualise quarter-on-quarter growth.

HALS: volume, export mix, and FY27 revenue expectation

HALS remained a central theme in the quarter. The company said the HALS business contributed 22% of sales in Q1 FY27. It also noted that exports accounted for nearly 50% of HALS sales, indicating a more diversified geographical mix versus earlier periods.

On operating metrics, the CFO stated that HALS volumes were approximately 1,000 tons in the quarter. The material also states an expectation of HALS revenue in the range of INR 250 crore to INR 300 crore for FY27, with an annualised Q1 run-rate referenced as INR 253 crore.

Product mix: diversification continues

Clean Science highlighted a gradual reduction in revenue concentration from its legacy portfolio. The top four legacy products’ share reportedly declined from 85% in Q4 FY23 to 60% in the current quarter. This shift was presented as part of the company’s broader product diversification strategy.

While the call commentary referenced external challenges impacting certain legacy lines, the reported improvement in overall consolidated revenue suggests that growth in newer segments, including HALS, helped offset some of the operating constraints.

Capex and subsidiary funding update

On the project pipeline, management said Performance Chemical 2 is expected to be commercialised by Q3 FY27. The company also disclosed a capital infusion of approximately INR 100 crore into its subsidiary during the quarter. Total investment in the subsidiary was stated at approximately INR 850 crore after this infusion.

The broader corporate update in the provided material also referenced incorporation of a wholly owned foreign subsidiary in the Netherlands by Clean Fino-Chem Limited.

Corporate actions and governance items

The board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The 23rd Annual General Meeting (AGM) is scheduled for September 12, 2026, via video conferencing.

The company also indicated a final dividend payment schedule. As per the provided information, payments are scheduled for September 30, 2026, to shareholders as of September 5, 2026.

Market reaction and investor access

The material notes that the stock was last quoted at 734.05, up 0.69% from the previous close of 729.05, and well below its 52-week high of 1,256.8. Separately, the company made the audio recording of the Q1 FY27 earnings call publicly available, citing compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording was uploaded to the company’s official website, providing investors access to management commentary alongside the published numbers.

Snapshot table: Q1 FY27 reported metrics

Timeline and key dates

Analysis: why the quarter matters

The quarter’s importance lies in the combination of record consolidated sales and a business environment marked by supply-chain and logistics constraints. The company’s disclosures connect the revenue outcome to improved realisations across products and the continued scaling of HALS, including stronger export contribution.

Another notable data point is the ongoing shift in product concentration, with the top four legacy products forming a smaller share of revenue compared with Q4 FY23. Alongside the planned commercialisation of Performance Chemical 2 and continued subsidiary investment (INR 850 crore total), the quarter sets up several operational milestones that investors will track through FY27.

Conclusion

Clean Science closed Q1 FY27 with record consolidated sales of about INR 264 crore and maintained reported margins across both consolidated and standalone results, while highlighting shipping delays and raw-material disruptions. The next confirmed milestones include the September 12, 2026 AGM, the dividend payment scheduled for September 30, 2026, and the planned commercialisation of Performance Chemical 2 in Q3 FY27.